Anti-cancer tgfb2 agents and immunotherapeutic agents
The combination therapy of TGF-β2 specific antisense agents, immune checkpoint inhibitors, and interleukin immunotherapy agents has solved the problems of low efficacy and large side effects of existing anticancer drugs, significantly improving the survival rate and long-term survival rate of cancer patients and reducing toxicity.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GMP BIOTECHNOLOGY LTD
- Filing Date
- 2024-06-05
- Publication Date
- 2026-06-09
AI Technical Summary
Existing anticancer drugs have limited efficacy, significant side effects, and high toxicity in treating cancer. There is a need for drug compositions and methods that can improve treatment effectiveness and reduce side effects.
A combination therapy of TGF-β2-specific antisense agents, immune checkpoint inhibitors, and interleukin immunotherapy agents was employed to enhance the immune system's ability to attack cancer cells by inhibiting TGF-β2 expression. This was combined with chemotherapy and standard care therapy, and biomarkers such as IRF5 and ITGAM were selectively used to identify subjects.
It significantly improved the survival time and long-term survival rate of cancer patients, reduced toxicity and adverse side effects, and showed a significant synergistic anti-cancer effect, especially in patients with high TGF-β2 and high IL-2 ratios.
Smart Images
Figure CN122180772A_ABST